3 hours Neumora Therapeutics (NASDAQ:NMRA) Rating Reiterated by Needham & Company LLCMarketBeat
Needham & Company LLC reaffirmed a “buy” rating and set a $23.00 price target on shares of Neumora Therapeutics in a research report on Friday.
XNeedham & Company LLC reaffirmed a “buy” rating and set a $23.00 price target on shares of Neumora Therapeutics in a research report on Friday.
X